The Availability of Compounded GLP-1 Some online compounding pharmacies have stopped marketing GLP-1 drugs in response to the FDA's announcement, or have pivoted and joined forces with GLP-1 manufacturers, now offering only the brand name anti-obesity medications
Stopping seven days prior was a risk factor for aspiration pneumonitis (odds ratio, 1.29), with higher risks seen for stopping five days and one day prior (odds ratios, 2.74 and 2.74, respectively)
In the Phase 1b trial of higher doses (9 mg and 10 mg), 95% of participants experienced at least one adverse event, but only one participant discontinued treatment due to side effects
After my second kid, the pounds just stuck around no matter what I tried
Novo Nordisk CEO Dustar: Obesity Has Eclipsed Diabetes at ADA as Lilly's Retatrutide Hits 28.3% Weight Loss When the chief executive of the world's most valuable obesity-drug company admits he's surprised that a diabetes conference has been overtaken by weight-loss medicine, pay attention
